Blood-based biomarkers such as cytokeratin 18, along with various gene polymorphisms (e.g., those in patatin-like phospholipase domain-containing protein 3 and transmembrane 6 superfamily member 2) have been demonstrated to correlate with NAFLD and its severity, and they can potentially be employed in point-of-care testing to risk stratify patients with NAFLD [48,49]. Here, TM6SF2 is linked to metabolic dysfunction-associated steatotic liver disease.